OR WAIT null SECS
CDMO, Vibalogics, has revealed that it will be acquired by a private equity firm, Ampersand Capital Partners.
Contract development and manufacturing organization, Vibalogics, has revealed in a May 29, 2019 press release that it will be acquired by a private equity firm, Ampersand Capital Partners.
Through the acquisition, Ampersand will invest in Vibalogics to expand its capabilities so that it can meet the growing industry demand for development and manufacturing of complex viral products. Currently, Vibalogics offers process development, manufacturing, and fill/finish of biopharmaceutical products and has a specific focus on viruses, live bacteria, and aseptic processing. The company employs 50 people at its facility in Cuxhaven, Germany.
“With the benefit of Ampersand as our partner, Vibalogics will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities,” said Stefan Beyer, PhD, CEO of Vibalogics. “The partnership solidifies Vibalogics’ existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer and genetic disorders. We are very pleased to have Ampersand on board as we take Vibalogics through to its next phase of growth.”
“Vibalogics is a leading company in its field. Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company,” added David Anderson, general partner at Ampersand. “We are looking forward to working with the team at Vibalogics to accelerate and continue its success in delivering cutting edge therapies to patients in need.”